Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation

Impact of PEG and PEG- b -PAGE modified PLGA on nanoparticle formation, protein loading and release

“…To overcome this problem the incorporation of proteins in the polymeric matrix of nanoparticles (NPs) appears to be a promising strategy (Barratt, 2003;Bramwell and Perrie, 2005;Csaba et al, 2006;SantanderOrtega et al, 2010). Numerous advanced drug delivery systems, such as NPs, microparticles and liposomes were developed in the last decades (Soppimath et al, 2001;Yadav et al, 2011).…”

The importance of antimicrobial peptides and their potential for therapeutic use in ophthalmology

“…antibodies) to enhance the circulation time and targeting properties of the formulations. Also, microspheres and nanoparticles composed of polymers may be useful to prolong the circulation time of peptides in the blood and to reduce the frequency of drug administration [77,80].…”

Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers

“…Biomacromolecules exhibit a complex structure with a high molecular weight (between 300 and 1,000,000 Da) and amphiphilic properties (Mitragotri et al, 2014). Moreover, biopharmaceuticals are labile compounds and prone to stability problems like aggregation and denaturation that can occur during manufacturing, storage, and administration (Cromwell et al, 2006;Yadav et al, 2011). If a protein is subjected to agitation or shear stress, changes in pH or ionic strength, light or temperature, its labile secondary structure can easily be disturbed which triggers the unfolding of the amino-acid chain and induces aggregation or denaturation and ultimately the reduction of biological activity (Cromwell et al, 2006;Frokjaer and Otzen, 2005;Mahler et al, 2009;Wang, 2005).…”